Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Mr. Rosenzweig is Associate General Counsel at C. R. Bard, Inc., a leading diversified medical device company. He leads the Corporate and Commercial Law group handling M&A, securities, global clinical affairs, compensation and benefits, and all other legal support of the U.S. commercial activities of the company. Mr. Rosenzweig participates in the Audit and Finance Committees of Bard’s board of directors and advises the company on corporate governance and disclosure matters. He serves as a member and Secretary of the company’s Disclosure Committee and Chair and Secretary of the 8-K subcommittee.
Prior to joining Bard, Mr. Rosenzweig served as Senior Vice President, General Counsel and Secretary of Phibro Animal Health Corporation, a manufacturer and marketer of animal health pharmaceuticals and specialty chemicals. From 2001 through 2004, Mr. Rosenzweig served as Senior Vice President, General Counsel and Secretary of IMPATH Inc., a leading publicly traded, cancer-focused laboratory that provided advanced pathology, and drug discovery and development services. Mr. Rosenzweig has also acted as an independent consultant for private equity and healthcare organizations. He spent three years as Director, Worldwide Licensing & Acquisitions at Johnson & Johnson where he was responsible for assessing and executing global business development opportunities for consumer companies with a focus on oral care and wound care. He began his legal career in New York as a corporate attorney, most recently with Kramer Levin Naftalis & Frankel LLP.
Mr. Rosenzweig has been Vice President of the American Cancer Society Metro New Jersey Regional Board of Advisors since 2004.
Rich earned his Juris Doctor degree from Boston University School of Law and a Bachelor of Arts degree in psychology (with a two-year concentration in biology) from Brandeis University.